Shares of biotechnology company Bluebird bio (NASDAQ:BLUE) are surging in the pre-market session today on receiving approval from the US. Food and Drug Administration (FDA) for its gene therapy Skysona. The therapy is targeted for the treatment of cerebral adrenoleukodystrophy (CALD) which is a neurodegenerative disease. Importantly, this is the first approved therapy by the FDA that has demonstrated a slowing of progression of dysfunction in boys with CALD which is a fatal condition. The therapy is expected to be commercially available by the end of this year.
https://www.tipranks.com/news/blubird-bio-nasdaqblue-rises-on-gene-therapy-approval?utm_source=advfn.com&utm_medium=referral
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more bluebird bio Charts.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more bluebird bio Charts.